ArticleInternational journal of hypertension2013
Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT.
Article in International journal of hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement.Journal of human hypertension · 2025Guideline
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.Hypertension (Dallas, Tex. : 1979) · 2018Guideline
- Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- The Global Burden of Resistant Hypertension and Potential Treatment Options.European cardiology · 2024Review
- No Association BetweenDiabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program.Frontiers in genetics · 2023Article
- When blood pressure refuses to budge: exploring the complexity of resistant hypertension.Frontiers in cardiovascular medicine · 2023Review
- Optimizing identification of resistant hypertension: Computable phenotype development and validation.Pharmacoepidemiology and drug safety · 2020Article
- Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.American journal of hypertension · 2019Article
- Natural selection and local adaptation of blood pressure regulation and their perspectives on precision medicine in hypertension.Hereditas · 2019Review
- Excessive dietary sodium intake and elevated blood pressure: a review of current prevention and management strategies and the emerging role of pharmaconutrigenetics.BMJ nutrition, prevention & health · 2018Review
- Genetics of resistant hypertension: a novel pharmacogenomics phenotype.Current hypertension reports · 2015Review
- An update on the pharmacogenetics of treating hypertension.Journal of human hypertension · 2015Review
- Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.Journal of the American Heart Association · 2014Article
- Angiotensinogen Variants among Resistant Hypertensive Patients.International journal of hypertension · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Treatment resistant hypertension (TRH) is defined as uncontrolled hypertension (HTN) despite the use of ≥3 antihypertensive medication classes or controlled HTN while treated with ≥4 antihypertensive medication classes. Risk factors for TRH include increasing age, diminished kidney function, higher body mass index, diabetes, and African American (AA) race. Importantly, previous studies suggest a genetic role in TRH, although the genetics of TRH are largely understudied. With 2203 treatment resistant cases and 2354 treatment responsive controls (36% AA) from the Genetics of Hypertension Associated Treatment Study (GenHAT), we assessed the association of 78 candidate gene polymorphisms with TRH status using logistic regression. After stratifying by race and adjusting for potential confounders, there were 2 genetic variants in the AGT gene (rs699, rs5051) statistically significantly associated with TRH among white participants. The Met allele of rs699 and the G allele of rs5051 were positively associated with TRH: OR = 1.27 (1.12-1.44), P = 0.0001, and OR = 1.36 (1.20-1.53), P < 0.0001, respectively. There was no similar association among AA participants (race interaction P = 0.0004 for rs699 and P = 0.0001 for rs5051). This research contributes to our understanding of the genetic basis of TRH, and further genetic studies of TRH may help reach the goal of better clinical outcomes for hypertensive patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.